Clinical Trials Directory

Trials / Unknown

UnknownNCT05801900

Intravenous Ibuprofen Versus Ketorolac in Bariatric Surgery

Intravenous Ibuprofen Versus Ketorolac for Perioperative Pain Control in Morbid Obese Patients Undergoing Bariatric Surgery: a Randomized Controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
116 (estimated)
Sponsor
Cairo University · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The aim of the current study is to compare the analgesic effects of both drugs in patients with obesity undergoing bariatric surgery.

Detailed description

Upon arrival to the operating room, routine monitors (electrocardiogram, pulse oximetry, and non-invasive blood pressure monitor) will be applied; intravenous line will be secured, and prophylactic antiemetic will be provided in the form of slow intravenous injection of 5 mg dexamethasone drugs. Anesthesia Anesthesia will be induced with 2 mg/kg propofol, 2 mcg/kg fentanyl (lean body weight), and tracheal intubation will be facilitated by 0.6 mg/kg ideal body weight rocuronium after loss of consciousness. Anesthesia will be maintained with isoflurane 1-1.2% in oxygen and 0.1 mg/kg rocuronium every 30 minutes. Fentanyl boluses of 1 mcg/kg will be given if heart rate or/and systolic blood pressure \>120% of baseline. Postoperatively, pain assessments using the visual analogue scale (VAS) will be performed at rest and during movement (knee flexion) at 0.5, 4, 10, 18, and 24 h after leaving the operating room. If the VAS score is \> 3 intravenous nalbuphine 0.1-0.2 mg/kg (lean body weight) titrated to response with maximum single dose of 20 mg and maximum daily dose of 160 mg. Intravenous ondansetron 4 mg will be given to treat postoperative nausea or vomiting

Conditions

Interventions

TypeNameDescription
DRUGKetorolac group30 min preoperatively then every 8 hours postoperatively
DRUGIbuprofen group30 min preoperatively then every 8 hours postoperatively

Timeline

Start date
2023-04-01
Primary completion
2023-06-01
Completion
2023-06-01
First posted
2023-04-06
Last updated
2023-04-06

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT05801900. Inclusion in this directory is not an endorsement.